Search clinical trials for: QL0911

Total 10 results

Qilu Pharmaceutical Co., Ltd.

Completed

Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia

Chemotherapy-induced Thrombocytopenia

China
Qilu Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia

China
Qilu Pharmaceutical Co., Ltd.

Recruiting

Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia

Chemotherapy-induced Thrombocytopenia

China
OnQuality Pharmaceuticals (USA) LLC

Active, not recruiting

A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients (NOVA-II)

Hand-Foot Skin Reaction (HFSR)

United States, China, India
Ascletis Pharmaceuticals Co., Ltd.
Beijing YouAn Hospital

Completed

A Study of the Pharmacokinetics of ASC09F in Healthy Subjects

Healthy

China
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects

DLBCL

Bulgaria, Estonia, France, Hungary, Italy, Latvia, Poland, Russian Federation, Spain, Ukraine
Teva Pharmaceutical Industries, Ltd.

Completed

TL011 in Severe, Active Rheumatoid Arthritis Patients

Rheumatoid Arthritis

Czechia, Hungary, Italy, Spain, United Kingdom
Tibotec Pharmaceuticals, Ireland

Completed

PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir

HIV-1
Tibotec Pharmaceuticals, Ireland

Withdrawn

PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.

HIV Infections

Netherlands
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients

Human Immunodeficiency Virus Type 1

Germany

3

Subscribe